Cathy's FotoPage

By: Cathy Linenberger

[Recommend this Fotopage] | [Share this Fotopage]
View complete fotopage

Sunday, 21-Sep-2014 08:46 Email | Share | Bookmark
Inplay From - Yahoo Finance

The yellow metal pulled back from its session high of $1239.10 and settled 0.6% lower, brining losses for the week to 2.8%. Dec silver rose $0.01 to $18.61/oz Silver chopped around between positive and negative territory, with prices dipping as low as $18.51 in late morning action. It eventually settled kim kardashian and 0.1% higher, booking a loss of 2.9% for the week. Dec copper rose 2 cents to $3.11/lb 1:24 pm Synthetic Biologics receives Orphan Drug Designation for SYN-005 treatment for whooping cough (pertussis) ( SYN ) : Co announced that the FDA has granted Orphan Drug designation to the co's proprietary SYN-005 monoclonal antibody combination for the treatment of Pertussis, more commonly known as whooping cough. In the U.S., Orphan Drug Designation provides a variety of incentives, including seven years of market exclusivity, should SYN-005 receive FDA approval for the treatment of Pertussis. Synthetic Biologics is developing SYN-005 through its Exclusive Channel Collaboration with Intrexon (XON) and academic researchers at The University of Texas at Austin to target and neutralize the pertussis toxin in order to reduce morbidity and mortality in infected infants. 1:23 pm Oct natural gas pushes to new session high; now up 0.6% at $3.85 (:COMDX) : 1:22 pm S&P -13 and Nasdaq Comp -27 join Dow -87 at fresh afternoon/session lows (:TECHX) : 1:15 pm Dow -73 slips to fractional new low -- S&P -11, Nasdaq Comp -22 (:TECHX) : 1:01 pm TriVascular Technologies presented three-year ovation pivotal trial data that showed 100% freedom from aneurysm rupture ( TRIV ) : Co presented three-year primary safety and performance metrics from the Ovation Pivotal Trial today at the 2014 Joint this link Annual Meeting of the New England Vascular Society and Eastern Vascular Society. At the three-year where is kim kardashian from mark, the study continued to show strong clinical results. Specifically, the data showed 100% freedom from aneurysm rupture, 100% freedom from conversion to open surgical repair, 100% freedom from Type I & III endoleaks, and 100% freedom from device migration. <br>Source:

View complete fotopage

© Pidgin Technologies Ltd. 2016